Skip to content

Research at St Andrews

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Research output: Contribution to journalArticlepeer-review

Author(s)

Eleftheria Vasileiou, Colin R Simpson, Ting Shi, Steven Kerr, Utkarsh Agrawal, Ashley Akbari, Stuart Bedston, Jillian Beggs, Declan Bradley, Antony Chuter, Simon de Lusignan, Annemarie B Docherty, David Ford, FD Richard Hobbs, Mark Joy, Srinivasa Vittal Katikireddi, James Marple, Colin McCowan, Dylan McGagh, Jim McMenamin & 12 more Emily Moore, Josephine LK Murray, Jiafeng Pan, Lewis Ritchie, Syed Ahmar Shah, Sarah Stock, Fatemeh Torabi, Ruby SM Tsang, Rachael Wood, Mark Woolhouse, Chris Robertson, Aziz Sheikh

School/Research organisations

Abstract

Background The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national vaccination programmes in the UK and several other countries. Studying the real-world effects of these vaccines is an urgent requirement. The aim of our study was to investigate the association between the mass roll-out of the first doses of these COVID-19 vaccines and hospital admissions for COVID-19. 

Methods We did a prospective cohort study using the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19—EAVE II—database comprising linked vaccination, primary care, real-time reverse transcription-PCR testing, and hospital admission patient records for 5·4 million people in Scotland (about 99% of the population) registered at 940 general practices. Individuals who had previously tested positive were excluded from the analysis. A time-dependent Cox model and Poisson regression models with inverse propensity weights were fitted to estimate effectiveness against COVID-19 hospital admission (defined as 1–adjusted rate ratio) following the first dose of vaccine. 

Findings Between Dec 8, 2020, and Feb 22, 2021, a total of 1 331 993 people were vaccinated over the study period. The mean age of those vaccinated was 65·0 years (SD 16·2). The first dose of the BNT162b2 mRNA vaccine was associated with a vaccine effect of 91% (95% CI 85–94) for reduced COVID-19 hospital admission at 28–34 days post-vaccination. Vaccine effect at the same time interval for the ChAdOx1 vaccine was 88% (95% CI 75–94). Results of combined vaccine effects against hospital admission due to COVID-19 were similar when restricting the analysis to those aged 80 years and older (83%, 95% CI 72–89 at 28–34 days post-vaccination). 

Interpretation Mass roll-out of the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines was associated with substantial reductions in the risk of hospital admission due to COVID-19 in Scotland. There remains the possibility that some of the observed effects might have been due to residual confounding. 

Funding UK Research and Innovation (Medical Research Council), Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK.
Close

Details

Original languageEnglish
Pages (from-to)1646-1657
JournalThe Lancet
Volume397
Issue number10285
Early online date23 Apr 2021
DOIs
Publication statusPublished - 1 May 2021

    Research areas

  • COVID-19

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Temporal trends and forecasting of COVID-19 hospitalisations and deaths in Scotland using a national real-time patient-level data platform: a statistical modelling study

    Simpson, C. R., Robertson, C., Vasileiou, E., Moore, E., McCowan, C., Agrawal, U., Stagg, H. R., Docherty, A., Mulholland, R., Murray, J. LK., Ritchie, L. D., McMenamin, J. & Sheikh, A., 5 Jul 2021, (E-pub ahead of print) In: The Lancet Digital Health. Online First, 9 p.

    Research output: Contribution to journalArticlepeer-review

  2. Ethnic and social inequalities in COVID-19 outcomes in Scotland: protocol for early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II)

    Henery, P., Vasileiou, E., Buchanan, D., Harrison, E., Leyland, A., Alexis, T., Robertson, C., Agrawal, U., Ritchie, L., Stock, S., McCowan, C., Docherty, A., Kerr, S., Marple, J., Wood, R., Moore, E., Simpson, C., Shiekh, A. & Katikireddi, S., 2 Jul 2021, In: BMJ Open.

    Research output: Contribution to journalArticlepeer-review

  3. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

    Simpson, C. R., Shi, T., Vasileiou, E., Katikireddi, S. V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S. A., Ritchie, L. D., Murray, J., Pan, J., Bradley, D. T., Stock, S. J., Wood, R., Chuter, A., Beggs, J., Stagg, H. R., Joy, M., Tsang, R. S. M. & 10 others, de Lusignan, S., Hobbs, R., Lyons, R. A., Torabi, F., Bedston, S., O'Leary, M., Akbari, A., McMenamin, J., Robertson, C. & Sheikh, A., 9 Jun 2021, (E-pub ahead of print) In: Nature Medicine. 16 p.

    Research output: Contribution to journalArticlepeer-review

  4. Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database

    Mulholland, R. H., Vasileiou, E., Simpson, C. R., Robertson, C., Ritchie, L. D., Agrawal, U., Woolhouse, M., Murray, J. L. K., Stagg, H. R., Docherty, A. B., McCowan, C., Wood, R., Stock, S. J. & Sheikh, A., 16 Apr 2021, (E-pub ahead of print) In: International Journal of Epidemiology. 11 p., dyab028.

    Research output: Contribution to journalArticlepeer-review

  5. Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality

    Flook, M., Jackson, C., Vasileiou, E., Simpson, C. R., Muckian, M. D., Agrawal, U., McCowan, C., Jia, Y., Murray, J. L. K., Ritchie, L. D., Robertson, C., Stock, S. J., Wang, X., Woolhouse, M. E. J., Sheikh, A. & Stagg, H. R., 12 Apr 2021, In: BMC Infectious Diseases. 21, 23 p., 342.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. Mass infection is not an option: we must do more to protect our young

    Gurdasani, D., Drury, J., Greenhalgh, T., Griffin, S., Haque, Z., Hyde, Z., Katzourakis, A., McKee, M., Michie, S., Pagel, C., Reicher, S., Roberts, A., West, R., Yates, C. & Ziauddeen, H., 7 Jul 2021, (E-pub ahead of print) In: The Lancet. In Press

    Research output: Contribution to journalComment/debate

  2. School reopening without robust COVID-19 mitigation risks accelerating the pandemic

    Gurdasani, D., Alwan, N. A., Greenhalgh, T., Hyde, Z., Johnson, L., McKee, M., Michie, S., Prather, K. A., Rasmussen, S. D., Reicher, S., Roderick, P. & Ziauddeen, H., 27 Mar 2021, In: The Lancet. 397, 10280, p. 1177-1178 2 p.

    Research output: Contribution to journalLetter

  3. John Keats, medicine, and poetry

    Roe, N., 13 Mar 2021, In: Lancet. 397, 10278, p. 962-963 2 p.

    Research output: Contribution to journalLetter

  4. The COVID-19 vaccines rush: participatory community engagement matters more than ever

    Burgess, R. A., Osborne, R. H., Yongabi, K. A., Greenhalgh, T., Gurdasani, D., Kang, G., Falade, A. G., Odone, A., Busse, R., Martin-Moreno, J. M., Reicher, S. & McKee, M., 10 Dec 2020, (E-pub ahead of print) In: The Lancet. In Press

    Research output: Contribution to journalComment/debatepeer-review

ID: 273372735

Top